Ascendis Pharma Launches Share Repurchase Program

• Ascendis Pharma A/S announced the program on September 14, 2026.
• The program may be modified, suspended or terminated at any time without notice.
• Repurchases are not mandatory under the program's terms.
• Timing of purchases will be determined based on market conditions, share price and other factors.

Program Details

Ascendis Pharma A/S announced a share repurchase program on September 14, 2026. The company said the program may be modified, suspended or terminated at any time without notice.

There is no mandatory repurchase requirement under the program. Repurchase timing will be determined based on market conditions, share price and other factors.

• Open market purchases
• Privately negotiated transactions
• Block trades
• Accelerated share repurchase transactions
• Purchases through 10b5-1 trading plans, or any combination of these methods

Company Profile

Ascendis Pharma is a global biopharmaceutical company focused on applying its innovative TransCon technology platform. The company is headquartered in Copenhagen, Denmark, and its shares trade on Nasdaq under the ticker ASND.

Ascendis Pharma maintains additional facilities in Europe and the United States. The company filed its annual report on February 11, 2026.

Contacts

• Investor contact: +1 (650) 519-7494
• Media contact: +1 (650) 709-8875